Skip to main content
SpringerLink
Log in

Polychemotherapie des Magenkarzinoms

  • Conference paper
Magenkarzinom

  • 23 Accesses

Zusammenfassung

Das Magenkarzinom steht in der Todesursachenstatistik der malignen Neoplasien der Bundesrepublik Deutschland an zweiter Stelle. Jährlich werden 28 Sterbefälle auf 100000 Einwohner registriert [47].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aabo K, Pedersen H, Rorth M (1985) Cisplatin in the treatment of advanced gastric carcinomas: a phase II study. Cancer Treat Rep 69: 449–450

    PubMed  CAS  Google Scholar 

  2. Ahlgren JD, Schmith FP, Harvey J, Kales AN, Woolley PV, Schein PS (1984) A phase II study of FAM (5-FU, adriamycin and mitomycin-C) plus triazinate (T) for advanced measurable gastric cancer. Proc ASCO 3: 145

    Google Scholar 

  3. Aaoyama M, Hirose H, Adachi N, Udo K, Oshima K, Kobayashi S (1981) Comparison of combination therapy of 5-fluorouracil, mitomycin C and adriamycin (FAM) and mitomycin C, 5-fluorouracil and cytosine arabinoside (MFC) for advanced gastric cancer. Gan To Kagaku Ryoho 8: 757–762

    Google Scholar 

  4. Arbuck SG, Douglass HO, Rrave F, Milliron S, Barconi M, Nava H, Emrich LJ, Rustum YM (1987) A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 5: 1150–1156

    PubMed  CAS  Google Scholar 

  5. Asakawa H, Otawa K, Watari J (1971) High energy x-ray therapy for stomach carcinoma, second report: the evaluation of radiotherapy for the early and the inoperable stomach carcinoma. Nippon Acta Radiol. 31: 505–511

    PubMed  CAS  Google Scholar 

  6. Asakawa H, Takeda T (1973) High energy x-ray therapy of gastric carcinoma. J Jpn Soc Cancer Ther 8: 362–369

    CAS  Google Scholar 

  7. Baker LH, Vaitkevicius VK, Gehan E (1976) Randomized prospektive trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer. Cancer Treat. Rep. 60; 733–737

    PubMed  CAS  Google Scholar 

  8. Bedikian AY, Chen TT, Khankhanian N, Heilbrun LK, McBride CM, McMurtrey MJ, Bodey GP (1984) The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 2: 305–310

    PubMed  CAS  Google Scholar 

  9. Beer M, Cocconi G, Ceci G, Varini M, Cavalli F (1983) A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19: 717–720

    Article  PubMed  CAS  Google Scholar 

  10. Behre W, Brömsen J, Harstrick A, Reile D, Meyer H-J, Jähne J, Schmoll H-J, Link H. Wilke H : Antitumor activity of anthracyclines in human gastric cancer xenografts depending on time scheduling. Blut 55: 224

    Google Scholar 

  11. Bengmark S, Jeppson B (1982) Staging of liver metastases In: Wess L, Gilberg HA (eds) Liver metastases. Hall, Boston pp 268–274

    Google Scholar 

  12. Beretta G, Fraschini P, Labianca R, Luporini G (1982) The value of FAM polychemotherapy in advanced gastric carcinoma. Proc Am Soc Clin Oncol 103: C-400

    Google Scholar 

  13. Beretta G, Fraschini P, Ravaioli A, Amadori D, Luperini G (1983) FAM/FAMB polychemotherapy for advanced carcinoma of the stomach (ACS): a randomized study. Proc ASCO 2: C-514

    Google Scholar 

  14. Beretta G, Fraschini P, Labianca R, Arnoldi E, Pancera G, Tedeschi M, Tedeschi L, Luporini G (1986) Weekly 5-fluorouracil (F) versus combination chemotherapy for advanced gastrointestinal carcinomas. A prospective study program. (Abstract) Proc Am Soc Clin Oncol 94: C-367

    Google Scholar 

  15. Bernath AM, Thomsvard CT (1979) Treatment of advanced gastric carcinoma with BCNU, adriamycin, 5-FU and mitomycin-C (BAFMi). Proc. ASCO 20: C-87

    Google Scholar 

  16. Biran H, Sulkes A (1984) A possible dose-response relationship in „FAM“ chemotherapy for advanced gastric cancer (Abstract) Proc Am Soc Clin Oncol 132: C-515

    Google Scholar 

  17. Bleiberg H (1985) Prognostic significance of pathological staging in gastrointestinal tumors. Eur J Cancer Clin Oncol 21: 655–658

    Article  PubMed  CAS  Google Scholar 

  18. Borchard F, Sons HU (1985) Klassifizierung des Magenkarzinoms aus pathologisch-anatomischer Sicht. Therapiewoche 35: 161–169

    Google Scholar 

  19. Bruckner HW, Lokich JJ, Stablein DM (1982) Studies of Bakers antifol, methotrexate and razoxane in advanced gastric cancer. A gastrointestinal tumor study group report. Cancer Treat Rep 66: 1713–1717

    PubMed  CAS  Google Scholar 

  20. Bruckner HW, Stablein DM (1983) Sites of treatment failure: gastrointestinal tumor study group analyses of gastric, pancreatic, colorectal trials. Cancer Treat Rep 2: 199–211

    Google Scholar 

  21. Cartei G (1985) 5-Fluorouracil, Adriamycin und Mitomycin C beim metastasierenden Magenkarzinom. In: Nagel GA, Bach F, Bartsch HH, Mitomycin ‘85. Aktuelle Onkologie. Zuckerschwerdt, München, S 56–64

    Google Scholar 

  22. Cazap EL, Gisselbrecht Ch, Smith FP, Estevez RA, Alvarez CA, Lagarde C, Hannols A (1986) Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep 70: 781–783

    PubMed  CAS  Google Scholar 

  23. Childs DS, Moertel CG, Holbrook MA, Reitemeier RJ, Colby M (1986) Treatment of unresectable adenocarcinoma of the stomach with a combination of 5-Fluorouracil and radiation. AJR 102: 541–546

    Article  Google Scholar 

  24. Clarke JS, Cruze K, El Farra S, Longmire WP (1961) The natural history and results of surgical therapy for carcinoma of the stomach. An analysis of 250 cases. Am J Surg 102: 143

    Article  PubMed  CAS  Google Scholar 

  25. Cocconi G, DeLisi V, Di Blasio B (1982) Randomized comparison of 5-Fu alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer Cancer Treat Rep 66: 1263–1266

    PubMed  CAS  Google Scholar 

  26. Comis RL (1979) Mitomycin C in gastric cancer. In: Mitomycin C-current status and new developments. Carter SK, Crooke ST (eds) Academic Press, New York, pp 129–137

    Google Scholar 

  27. Cullinan SA, Moertel CG, Fleming ThR, Rubin JR, Krook JE, Everson LK, Windschitl HE et al. (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 12: 2061–2066

    Article  Google Scholar 

  28. Dalley D, Erlichman C, Fine S (1986) Treatment of advanced gastric carcinoma with mitomycin and doxorubicin. Cancer Treat Rep 70: 897–898

    PubMed  CAS  Google Scholar 

  29. De Lisi V, Cocconi G, Tonato M, Di Costanzo F, Leonardi F, Soldani M (1986) Randomized comparison of 5-Fu alone or combined with carmustine, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian clinical research oncology group (GOIRC). Cancer Treat Rep 70: 481–485

    PubMed  Google Scholar 

  30. Diehl JT, Herrmann RE, Cooperman AM, Hoerr SO (1983) Gastric carcinoma. A ten year review. Ann Surg 198: 9–12 (1983)

    Article  PubMed  CAS  Google Scholar 

  31. Dixon WJ, Longmire WP, Holden WD (1971) Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: ten year follow-up. Ann Surg 173: 16–19 (1971)

    Article  Google Scholar 

  32. Douglass HO Jr, Lavin PT, Goudsmit A, Klaasen DJ, Paul AR (1984) An eastern cooperative oncology group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2: 1372–1381

    PubMed  Google Scholar 

  33. Dupont JB, Lee JR, Burton GR, Jonson A (1978) Adenocarcinoma of the stomach: review of 1497 cases. Cancer 41: 941–953

    Article  PubMed  Google Scholar 

  34. Earl HM, Coombs RC, Schein PS (1984) Cytotoxic chemotherapy for cancer of the stomach. Clin Oncol 3: 351–369

    CAS  Google Scholar 

  35. Engstrom P, Lavin PT, Douglas HO, Brunner KW (1985) Postoperative adjuvant 5-fluoroura-cil plus methyl-CCNU therapy for gastric cancer patients. Cancer 55: 1868–1873

    Article  PubMed  CAS  Google Scholar 

  36. Falkson G (1965) Halogenated pyrimidines as radiopotentiators in the treatment of stomach cancer. Prog Biochem Pharmacol 1: 695–700

    Google Scholar 

  37. Falkson G, Falkson HC (1969) Fluorouracil and radiotherapy in gastrointestinal cancer. Lancet 2: 1252–1259

    Article  PubMed  CAS  Google Scholar 

  38. Fielding JWL, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa A, Brookes VS et al (1983) An interim report of a prospective randomized controlled study of adjuvant chemotherapy in operable gastric cancer. World J Surg 7: 390–399

    Article  PubMed  CAS  Google Scholar 

  39. Figoli F, Galligioni E, Crivellari D, Vaccher E, Lo Re G, Tumolo S, Veronesi A et al. (1986) Cisplatin (DDP) in combination with adriamycin (A) and fluorouracil (F) (DAF) in advanced gastric cancer — a phase II study. (Abstract) Proc Am Soc Clin Oncol 95 : C-369

    Google Scholar 

  40. Fornasiero A, Cartei G, Daniele O, Fosser V, Fiorentino MV (1984) FAM2 regimen in disseminated gastric cancer. Tumori 70: 77–80

    PubMed  CAS  Google Scholar 

  41. Galiano R, McCracken JD, Chen T (1983) Adjuvant chemotherapy with 5-fluorouracil, adriamycin, and mitomycin (FAM) in gastric cancer. Proc. ASCO 2: 114 (1983)

    Google Scholar 

  42. Gastrointestinal Tumor Study Group: (1982) A combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 49:1771–1777

    Article  Google Scholar 

  43. Gastrointestinal Tumor Study Group (1982) Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49:1116–1122

    Article  Google Scholar 

  44. The Gastrointestinal Tumor Study Group (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1871–1876

    Google Scholar 

  45. The Gastrointestinal Tumor Study Group (1984) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53: 13–17

    Article  Google Scholar 

  46. Gelber RD, Zelen M (1985) Planning and reporting of clinical trials. In: Calabresi PC, Schein PC, Rosenberg S (eds) Medical oncology. Macmillan, New York, pp 406–425

    Google Scholar 

  47. Statistisches Bundesamt Wiesbaden (Hrsg) (1984) Gesundheitswesen, Fachserie 12. Todesursachen 1983. Kohlhammer, Stuttgart, S 12–19

    Google Scholar 

  48. Gisselbrecht C, Smith FP, MacDonald JS, Korsmeyer SJ, Boiron M, Woolley PV, Schein P (1983) The effect of sequential addition of the nitrourea, chlorozotocin, to the FAM combination in advanced gastric cancer. Cancer 51: 1792–1794

    Article  PubMed  CAS  Google Scholar 

  49. Gunderson LL, Hoskins B, Cohen AM, Kaufman S, Wood WC, Carey RW (1983) Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys 9: 965–975

    Article  PubMed  CAS  Google Scholar 

  50. Haas C, Oishi N, McDonald B, Coltman C, O’Bryan R (1983) Southwest oncology group phase II-III gastric cancer study: 5-fluorouracil, adriamycin, and mitomcin C±vincristine (FAM vs V-FAM) compared to chlorozotocin (CZT), M-AMSA, and dihydroxyanthracene-dione (DHAD) with unimpressive differences. (Abstract) Proc Am Soc Clin Oncol (2) 122: C-478

    Google Scholar 

  51. Haas L, Vaitkevicius V, Bukowski R, Moore D, Mansfield K (1980) Southwest oncology group (SWOG) pilot study of radiotherapy (R) + 5-fluorouracil (F) + adriamycin + mitomycin C (M) in patients with minimal residual gastric cancer. (Abstract) Proc Am Soc Clin Oncol 342:C-439

    Google Scholar 

  52. Haim N, Cohen Y, Honigman J, Robinson E (1982) Treatment of advanced gastric carcinoma with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Chemother Pharmacol 8: 277–280

    Article  PubMed  CAS  Google Scholar 

  53. Haim N, Epelbaum R, Cohen Y, Robinson E (1984) Further studies in the treatment of advanced gastric cancer by 5-fluorouracil, adriamycin (doxorubicin), and mitomycin C (modified FAM). Cancer 54:1999–2002

    Article  PubMed  CAS  Google Scholar 

  54. Herrmann R, Fritze D, Queißer W, Flechtner H, Ho AD, Schlag P, König H (1984) Chemotherapie des Magenkarzinoms. Dtsch Med Wochenschr 109:1704

    Google Scholar 

  55. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Kheen RJ (1983) Efficacy of prolonged intermittend therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 52: 1105–1110

    Article  PubMed  CAS  Google Scholar 

  56. Imanaga H, Nakazato H (1977) Results of surgery for gastric cancer and effect of adjuvant mitomycin-C on cancer recurrence. World J Surg 1: 213–221

    Article  Google Scholar 

  57. Kantarjian H, Ajani JA, Karlin DA (1985) Cis-Diamminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 42: 69–71

    Article  PubMed  CAS  Google Scholar 

  58. Karlin DA, Stroehlein JR, Bennets RW, Jones RD, Heifetz LJ, Mahal PS (1982) Phase I-II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastrooesophageal junction, and pancreas. Cancer Treat Rep 66: 1613–1617

    PubMed  CAS  Google Scholar 

  59. Kelsen DP, Magill G, Cheng E, Coonley C, Yagoda A (1982) Phase II trial of Etoposide (VP16) in the treatment of upper gastrointestinal malignancies. (Abstract) Proc Am Soc Clin Oncol 96: C-371

    Google Scholar 

  60. Kim NK (1984) Chemotherapy of advanced gastric carcinoma with 5-Fluorouracil, adriamy-cin, mitomycin (FAM), and 5-fluorouracil, adriamycin, cisplatin (FAP) combinations: experience in Korea. In: Ogawa M, Muggia FM, Rozencweig M (eds) Adriamycin, its expanding role in cancer treatment. Excerpta Medica, Amsterdam, pp 137–145

    Google Scholar 

  61. Kim RH, Huh K, Ahn Y, Im C, Hee Y, Hee K, Kim CS (1985) BCNU, cisplatin and 5-fluorouracil poly chemotherapy in advanced gastric cancer. Proc ASCO 4: 95

    Google Scholar 

  62. Kim RH, Kim CS (1986) Chemotherapy of advanced gastric cancer with mitomycin C, BCNU, cisplatin and 5-fluorouracil in combination. Proc. ASCO 5: 78

    Google Scholar 

  63. Klein HO, Wickramanyake PD, Farrkh G-R (1986) 5-fluorouracil (5-Fu), adriamycin (ADM), and methotrexate (MTX)-A combination protocol (FAMTX) for treatment of metastasized stomach cancer. (Abstract) Proc Am Soc Clin Oncol 84: C-325

    Google Scholar 

  64. Kolaric K, Potrebica V, Stanovnik M (1986) Controlled phase III clinical study of 4-Epi-Doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology 43: 73–77

    Article  PubMed  CAS  Google Scholar 

  65. Kovach JS, Moertel CG, Schutt AJ (1974) A controlled trial of combined l,3-bis-(2-chloro-ethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33: 563–567

    Article  PubMed  CAS  Google Scholar 

  66. Koyama Y (1978) The current status of chemotherapy for gastric cancer in Japan with special emphasis on mitomycin-C. Recent Results Cancer Res 63: 135–147

    PubMed  CAS  Google Scholar 

  67. Koyama Y, Sugimachi K, Soejima K (1981) Evaluation of extensive lymphnode dissection for carcinoma of the stomach. World J Surg 5: 241–248

    Article  Google Scholar 

  68. Koyama Y, Kimura T (1978) Controlled clinical trials of chemotherapy as an adjuvant to surgery in gastric carcinoma. Proc 2nd Int Cancer Congr Buenos Aires, pp 1–21

    Google Scholar 

  69. Lacave, AJ, Wils H, Bleiberg E, Diaz-Rubio M, Clavel A, Planting O, Duez N (1986) Advanced and chemotherapy-resistant gastric cancer (GC): benefit of additional MeCCNU (Me) and evalutation of CDDP (P). E.O.R.T.C. Symposium on Gastrointestinal Tract Cancer, Heidelberg, May 29–30,1986

    Google Scholar 

  70. Lacave AJ, Wild J, Diaz-Rubio E, Clavel M, Planting A, Bleiberg H, Duez N, Dalesio O (1985) Phase II study of Cisplatin (DDP) in chemotherapy resistant carcinoma of the stomach Cancer Chemother Pharmacol 14 [Suppl]: 39–42

    Google Scholar 

  71. Lagunova IG, Cybulskij BA, Minerva OD, Sakaja IS (1978) Aufeinander folgende Strahlentherapie mit einem 25-meV Betatron und Chemotherapie mit Fluorouracil zur Behandlung von Kranken mit fortgeschrittenem Krebs des oberen Magenabschnittes. Radiobiol Radio-ther 13:307

    Google Scholar 

  72. Lavin PT, Bruckner HW, Plaxe SC (1982) Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 50: 2016–2023

    Article  PubMed  CAS  Google Scholar 

  73. Leichmann L, MacDonald B, Dindogru A, Samson M (1982) Platinum: a clinical active drug in advanced adenocarcinoma of the stomach. (Abstract) Proc Am Assoc Cancer Res 110: 430

    Google Scholar 

  74. Levi JA, Dalley DN, Aroney RS (1979) Improved combination chemotherapy in advanced gastric cancer. Br Med J 2: 1471–1473

    Article  PubMed  CAS  Google Scholar 

  75. Levi JA, Fox RM, Tattersall MH, Woods RL, Thomson D, Gill G (1986) Analysis of a prospective randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 4: 1348–1355

    PubMed  CAS  Google Scholar 

  76. Lopez M, Di Lauro L, Papaldo P, Conti EMS (1986) Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, adriamycin, and BCNU. Oncology 43: 288–291

    Article  PubMed  CAS  Google Scholar 

  77. Lopez M, Perno CF, Di Lauro L, Papaldo P (1984) 5-fluorouracil, adriamycin, BCNU (FAB) combination chemotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 12: 194–197

    Article  PubMed  CAS  Google Scholar 

  78. MacDonald JS, Gunderson LL, Cohn I Jr (1985) Cancer of the stomach. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. Lippincott, Philadelphia, pp 534–552

    Google Scholar 

  79. MacDonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, Smith F et al. (1980) 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination-chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533–536

    Article  PubMed  CAS  Google Scholar 

  80. Machover D, Goldschmidt E, Chollet P et al. (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685–696

    PubMed  CAS  Google Scholar 

  81. Moertel CG (1973) Therapy of advanced gastrointestinal cancer with the nitosoureas. Cancer Chemother Rep 4: 27–34

    CAS  Google Scholar 

  82. Moertel CG, Fleming T, O’Connell M, Schutt M, Rubin J (1984) A phase II trial of combined intensive course 5-Fu, adriamycin and cis-platinum in advanced gastric and pancreatic carcinoma, (abstract) Proc Am Soc Clin Oncol 137: C-535

    Google Scholar 

  83. Moertel CG, Lavin PT (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1863–1869

    PubMed  CAS  Google Scholar 

  84. Moertel CG, Rubin J, O’Connell MJ, Schutt AJ, Wieand HS (1986) A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053–1057

    PubMed  CAS  Google Scholar 

  85. Muro H, Romero Acuna L, Castagnari A, Blajman C, Schmilovich A, Hidalgo A, Fiori H, Bader M, Marantz A (1986) Sequentiell methotrexate, 5-flurouracil (high dose), and doxorubicin for advanced gastric cancer. Cancer Treat Rep 70: 1333–1334

    PubMed  CAS  Google Scholar 

  86. Nekajima T, Harashima S, Hirata M (1978) Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytol 22: 225–229

    Google Scholar 

  87. O’Connell MJ, Moertel CG, Lavin PT (1978) Adriamycin (A), 5-fluorouracil + mitomycin C+cytosin arabinoside (FMC), and 5-fluorouracil+adriamycin + methyl CCNU (FAMe) in advanced gastric carcinoma. Proc ASCO 19: C-146

    Google Scholar 

  88. O’Connell MJ (1985) Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3: 1032–1039

    PubMed  Google Scholar 

  89. Oshima K, Yamada T, Nonaka T, Aoyama M, Hirose H, Adachi N, Kobayachi S, Udo K (1982) Treatment of advanced G.I. cancer patients with 5-Fu, adriamycin, and mitomycin C (FAM). Proc 13th Intern Cancer Congress Seattle 8–15th Sept, p 665, Abstr 3977

    Google Scholar 

  90. Pannettiere FJ, Haas Ch, McDonald B, Costanzi JJ, Talley RW, Athens J, Oishi N (1984) Drug combinations in the treatment of gastric adenocarcinoma: a randomized southwest oncology group study. J Clin Oncol 2: 420–424 (1984)

    Google Scholar 

  91. Perry MC, Green MR, Mick R, Schein P (1986) Cisplatin in patients with gastric cancer: a cancer and leukemia group B phase II study. Cancer Treat Rep 70: 415–416 (1986)

    PubMed  CAS  Google Scholar 

  92. Preusser P, Achterrath W, Niederle N, Seeber S (1985) Cisplatin. Arzneimitteltherapie 2: 50–56

    Google Scholar 

  93. Preusser P, Wilke H, Achterrath W, Fink U, Meyer J, Schmitz-Hübner U, Bünte H (1987) Advanced gastric carcinoma: a phase II study with etoposide (E), adriamycin (A) and split course cisplatin (P) = EAP. Proc. ASCO 6: 75

    Google Scholar 

  94. Preusser P, Wilke H, Achterrath W, Fink U (1988) Chemotherapie des fortgeschrittenen Magenkarzinoms bei älteren Patienten und Risikopatienten. In: Hotz J, Meyer H-J, Schmoll H-J (Hrsg) Magenkarzinom. Springer, Berlin Heidelberg New York, S 186–197

    Google Scholar 

  95. Queißer W, Flechtner H, Heim ME, Henß H, Arnold H, Fritze D, Herrmann R (1986) 5-Flu-orouracil, 4-epidoxorubicin, and mitomycin C (FEM) for advanced gastric carcinoma, a phase II trial. J Cancer Res Clin Oncol 111 [Suppl], 85: Sto 16

    Article  Google Scholar 

  96. Robinson E, Haim N, Epelbaum R, Cohen Y (1985) Phase II trials in the treatment of advanced gastric cancer I -5-fluorouracil, adriamycin and mitomycin (FAM), II -cisplatin, adriamycin and 5-fluorouracil (DAF). (abstract) Proc Am Soc Clin Oncol 77: C-300

    Google Scholar 

  97. Rougier P, Droz JP, Amiel JL, Ruffier P, Theodore C, Kac J, Chavy A (1985) Gastric carcinoma: a phase II trial of chemotherapy with association 5-fluorouracil (5 FU), adriamycin (ADR) and cisplatin (DDP) (FAP protocol) in metastasized or inoperable patients. Preliminary results. Cancer Chemother Pharmacol 14 [Suppl]: 54–59

    Google Scholar 

  98. Schein PS, MacDonald JS, Hoth D, Wooley PV (1978) Mitomycin C: experience in the United States, with emphasis on gastric cancer. Cancer Chemother. Pharmacol. 1: 73–75

    Article  PubMed  CAS  Google Scholar 

  99. Schein PS, Smith FP, Dritschillo A, Stablein DM, Ahlgren JD (1983) Phase I-II trial of combined modality FAM plus split-course radiation (FAM-RT-FAM) for locally advanced gastric and pancreatic cancer: A midatlantic oncology program study. Proc Am Soc Clin Oncol 126: Abstr C-491

    Google Scholar 

  100. Schein PS, Coombes RC, Chilvers C (1986) For the international adjuvant trial in gastric cancer. A controlled trial of FAM (5-FU, doxorubicin, and mitomycin-C) chemotherapy as adjuvant treatment for resected gastric carcinoma: an interim report. Proc ASCO 5: 79

    Google Scholar 

  101. Scherdin G, Garbrecht M, Müllerleile U, Hossfeld DK (1986) Polychemotherapy with methotrexate in medium dosage range, 5-fluorouracil and adriamycin in advanced gastric carcinoma. J Cancer Res Clin Oncol 111 [Suppl]: 58

    Article  Google Scholar 

  102. Schnitzler G, Queißer W, Heim ME, König H, Katz R, Fritze D, Herrmann R et al. (1986) Phase III study of 5-Fu and Carmustine versus 5-Fu, Carmustine, and Doxorubicin in advanced gastric cancer. Cancer Treat Rep 70: 477–479

    PubMed  CAS  Google Scholar 

  103. Serlin O, Wolkoff JS, Amadeo JM, Keehn RJ (1969) Use of 5-Fluorodeoxyuridine (FudR) as an adjuvant to the surgical managenemt of carcinoma of the stomach. Cancer 24: 223–227

    Article  PubMed  CAS  Google Scholar 

  104. Simon RS (1985) Design and conduct of clinical trials In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. Lippincott, Philadelphia, pp 329–350

    Google Scholar 

  105. Spiesse B, Hermanek P, Scheibe O, Wagner G (Hrsg) (1985) UICC. TNM-Atlas. Springer, Berlin Heidelberg New York, pp 90–98

    Google Scholar 

  106. Wagener DJTh, Yap SH, Wobbes T, Burghouts JTM, van Dam FE, Hillen HFP, Hoogen-doorn GJ et al. (1985) Phase II trial of 5-fluorouracil, adriamycin, and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15: 86–87

    Article  PubMed  CAS  Google Scholar 

  107. Walder S, Green M, Muggia F (1985) The role of anthracyclines in the treatment of gastric cancer.

    Google Scholar 

  108. Walther HE (1948) Krebsmetastasen Schwabe, Basel S 363–377

    Google Scholar 

  109. Warren S (1933) Studies on tumor metastasis: IV. metastases of cancer of the stomach. N Engl J Med 209: 825–828

    Article  Google Scholar 

  110. Warwick M (1928) Analysis of one hundred and seventy-six cases of carcinoma of the stomach submitted to autopsie. Ann Surg 88: 216

    Article  PubMed  CAS  Google Scholar 

  111. Wilke H, Preusser P, Fink U, Schöber C, Stahl M, Link H, Fromm M et al. (1987) Phase I/II study with leucovorin/etoposide/5-fluorouracil in elderly patients or patients with cardiac risks suffering from advanced gastric cancer. Proc. ECCO 4: 37

    Google Scholar 

  112. Wilke H, Preusser P, Fink U, Klink M, Meyer J, Meyer H-J, Gunzer U, Schmoll H-J (1987) Preoperative „neoadjuvant“ chemotherapy with etoposide/adriamycin/cisplatin (EAP) in local advanced gastric cancer. Proc. ECCO 4: 32

    Google Scholar 

  113. Wilke H, Preusser P, Fink U, Achterrath W, Meyer H-J, Schmoll H-J, Poliwoda H: Präoperative „neoadjuvante“ Chemotherapie bei lokal fortgeschrittenen Magenkarzinomen. In: Hotz J, Meyer H-J, Schmoll H-J (Hrsg) Magenkarzinom. Springer, Berlin Heidelberg New York, S179–185

    Google Scholar 

  114. Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter Z, Duez N (1987) An EORTC gastrointestinal group evaluation of the combination of sequential Methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 4: 1799–1803

    Google Scholar 

  115. Wooley P, Smith F, Estevez R, Gisselbrecht C, Alvarez C, Boiron M, Machado C et al. (1981) A phase II trial of 5-Fu, adriamycin and cisplatin (FAP) in advanced gastric cancer, (abstract) Proc Am Soc Clin Oncol 455: C-481

    Google Scholar 

Download references

Authors
  1. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Preusser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Achterrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-J. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H.-J. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Poliwoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Medizin/Abteilung Gastroenterologie, Allgemeines Krankenhaus Celle, D-3100, Celle, Deutschland

    J. Hotz

  2. Zentrum für Chirurgie, Medizinischen Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    H.-J. Meyer

  3. Abteilung Hämatologie - Onkologie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    H.-J. Schmoll

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Wilke, H. et al. (1989). Polychemotherapie des Magenkarzinoms. In: Hotz, J., et al. Magenkarzinom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22121-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-22121-1_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-19001-1

  • Online ISBN: 978-3-662-22121-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation